2009 Top 10 Biopharmaceutical Companies Report
This edition of the Top 10 Biopharmas marks the end of an era. After this year, we’ll no longer be able to pencil in Amgen as our #1 biopharma, since Roche is poised to take that slot. A lot of major pharmas have talked about “becoming a global biopharma.” I wonder how many more of them will make the transition to this list in the next 5-10 years. (In fact, it’s not hard to imagine one or two follow-on biologics being enough to tip a generic company into the world of Top Biopharmas . . .)
On the positive side, the emergence of Alexion Pharma and its Soliris MAb allowed me to get a legit #10 company on the list. Remember: building this list is more of an art than a science, so if you can think of a biopharma that should be here — that is, a drug company that makes more than 60% of its pharma revenues from large-molecule drugs — drop me a line at gil@rodpub.com!
—Gil Y. Roth, Editor
| Top 10 Biopharmaceutical Companies | ||
| 01 | Amgen | $14,687 |
| 02 | Genentech | $10,531 |
| 03 | Novo Nordisk | $8,989 |
| 04 | Merck Serono | $7,338 |
| 05 | Baxter BioScience | $5,308 |
| 06 | Biogen Idec | $3,968 |
| 07 | Genzyme* | $3,751 |
| 08 | CSL Ltd.* | $2,961 |
| 09 | Allergan* | $1,311 |
| 10 | Alexion Pharma* | $259 |
Based on 2008 biopharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.
* PDF profiles only available for companies 7-10
Contributors
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
All profiles written by Gil Roth, except Baxter Bioscience by Kristin Brooks
The Lowe Down capsules written by Derek Lowe
All pipeline information compiled by Kristin Brooks
Looking for the Top 20 Pharma companies report? Look no further!
